Regardless, dual agonists targeting both GLP1R and GIPR decrease body weight and improve glucose tolerance in animal models of obesity and T2D in mice, non-human primates and obese patients with and without T2D [5,[16], [17], [18], [19]] with greater efficacy than GLP1R agonism alone. The gene discussed is GIPR; the disease is glucose measurement.